CYP19A1 and breast carcinoma: Studies have shown that SNPs in the CYP19A1, such as rs6493497 and rs7176005, are linked to higher baseline aromatase activity in postmenopausal breast cancer patients undergoing neoadjuvant AI therapy [43].